#BoehringerIngelheim has amended its partnership with #ClickTherapeutics on a #digitaltherapeutic (DTx) for #schizophrenia, transferring #commercialrights to the programme to the digital health specialist.

pharmaphorum.com/news/boehrin...

Lina Herhaus was awarded the Otto Meyerhof Prize from #BoehringerIngelheim and the #GBM at the 77. Mosbacher Kolloquium and presented her work on how IRGQ-mediated autophagy in MHC-I quality control drives tumor immune evasion. Congratulations, Lina!
@helmholtzhzi.bsky.social

Reconocimiento como enfermedad y abordaje integral: las claves del nuevo consenso sobre obesidad en España 'ConCiencia en Obesidad' es la iniciativa que busca que la sociedad reconozca la obesidad como enfermedad y abordarla desde una perspectiva científica, sanitaria y equitativa

#Pacientes | 🔹#BoehringerIngelheim impulsa 'ConCiencia en Obesidad', una plataforma para reconocer la #obesidad como enfermedad

Die CIO-Auf- und Aussteiger im Februar 2026 Diese IT-Chefinnen und -Chefs traten im Februar neue Herausforderungen an.

Die CIO-Auf- und Aussteiger im Februar 2026

Diese IT-Chefinnen und -Chefs traten im Februar neue Herausforderungen an. #cio #boehringeringelheim #ServiceNow #CWSBusinessServices www.cio.de/article/4137...

Boehringer gets FDA's second 'national priority' approval Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

#BoehringerIngelheim has become the second company to get a product approved under the #FDA's #nationalpriorityvoucher programme, claiming the go-ahead for first-line use of #lungcancer drug #Hernexeos.

pharmaphorum.com/news/boehrin...

Germany's #BoehringerIngelheim could sink up to $500 million into a #partnership with UK start-up #Sitryx focused on a family of #smallmolecule drugs for #autoimmune and #inflammatory diseases.

buff.ly/QiBzfGU

Boehringer Ingelheim consolida su compromiso con la formación continuada y la actualización técnica con su participación en las Jornadas de Porcino de la UAB y la AVPC​ - Foro Agro-Ganadero. Axón Comunicación Foro Agro-Ganadero ofrece información y formación especializada. Es una referencia en el sector Agro-ganadero

#axónvet #informaciónveterinaria #saludanimal #boehringerIngelheim #Porcino 

Made in Germany – Made in Canada 🇩🇪🇨🇦

For decades, German life science leaders like #Bayer, #BASF & #BoehringerIngelheim have helped shape Canada’s healthcare & agriculture sectors 🌱🧪🔬

Creating jobs, driving innovation & investing in research across the country.

Klinische Studien entdecken – einfach virtuell - Pharma Fakten Eine neue virtuelle Praxis von Boehringer Ingelheim bietet leicht verständliche Informationen rund um das Thema klinische Studien.

Eine neue #virtuellePraxis von #BoehringerIngelheim bietet leicht verständliche #Informationen rund um das Thema #klinischeStudien.

pharma-fakten.de/news/klinisc...

Boehringer Ingelheim ernennt Harsha Deshmukh zum IT-Chef Seit Februar 2026 leitet Deshmukh die IT des Pharma-Unternehmens. Er kommt von Infineon.

Seit Februar 2026 leitet Deshmukh die IT des Pharma-Unternehmens. Er kommt von Infineon. www.cio.de/article/4126... #cio #boehringeringelheim #itmanager

Boehringer drug scores in rare kidney disease FSGS Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.

A drug being developed by #BoehringerIngelheim for #COVID19 and reinvented as a potential therapy for #kidneydisease has now hit the mark in a #phase2 trial.

#BoehringerIngelheim has added another drug to its #immunology pipeline, #licensing an inflammatory bowel disease (#IBD) candidate from China's #Simcere in a deal that would be worth up to €1.05 billion ($1.25 billion).

buff.ly/IgGNk6v

Boehringer Ingelheim, Sara Frattini alla guida di Bidachem Spa (Adnkronos) - Un percorso professionale costruito nella ricerca scientifica e consolidato attraverso ruoli di crescente responsabilità porta oggi Sara Frattini alla guida di Bidachem S.p.a., polo chimico di eccellenza del Gruppo Boehri...

Boehringer Ingelheim, Sara Frattini alla guida di Bidachem Spa ... LEGGI TUTTO #BoehringerIngelheim #SaraFrattini #Bidachem #RicercaScientifica #ScienzeChimiche

Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

#Pfizer #obesity #weightloss #FosunPharma #YaoPharma #GLP1agonist #oralGIPanalogue #Metsera #EliLilly #NovoNordisk #Wegovy #ZealandPharma #metabolicdiseases #Roche #BoehringerIngelheim #GLP1glucagonagonist #StructureTherapeutics #AscletisPharma #WaveLifeSciences #Gubra
zurl.co/AwsrK

Boehringer Ingelheim hiring Senior or Principal Scientist of Human Genetics in Biberach an der Riß, Baden-Württemberg, Germany | LinkedIn Posted 3:27:12 PM. The PositionAbout us: Computational Innovation @ Boehringer Ingelheim…See this and similar jobs on LinkedIn.

Our Human Genetics team @boehringerglobal.bsky.social (Biberach site, Germany) is actively searching for an experienced Statistical Geneticist.

#StatisticalGenetics #HumanGenetics #BoehringerIngelheim #ComputationalInnovation #JobOpportunity

lnkd.in/g6QPihVE

ベーリンガーインゲルハイム、CDR-Lifeと抗体CDR111のライセンス契約を締結―自己免疫疾患を標的とした三特異性抗体の開発を加速 | STELLANEWS.LIFE ベーリンガーインゲルハイムは、CDR-Lifeと三特異性抗体CDR111のグローバルライセンス契約を締結。B細胞を選択的に除去する作用機序により、全身性エリテマトーデスなど自己免疫疾患への応用を見込む。

Boehringer Ingelheim signs global license deal with CDR-Life for trispecific antibody CDR111 targeting autoimmune diseases
🔗 stellanews.life/technology_c...

#BoehringerIngelheim #CDRLife

„Gesundheit ist Basis für Resilienz und Wohlstand“ - Pharma Fakten Médard Schoenmaeckers, Deutschlandchef von Boehringer Ingelheim, spricht im Interview über die Bedeutung der Pharmabranche für die Menschen in der Bundesrepublik.

Médard Schoenmaeckers, Deutschlandchef von #BoehringerIngelheim, spricht im #Interview über die Bedeutung der #Pharmabranche für die Menschen in der #Bundesrepublik.

pharma-fakten.de/news/gesundh...

Colosso biofarmaceutico tedesco punta a rafforzare legami con ecosistema cinese Il leader mondiale nel settore biofarmaceutico Boehringer Ingelheim, presenza abituale al CIIE, ha accelerato il lancio di prodotti in Cina sfruttando le politiche favorevoli e rafforzando il proprio impegno nel settore sanitario. (I...

Colosso biofarmaceutico tedesco punta a rafforzare legami con ecosistema cinese ... LEGGI TUTTO #biofarmaceutico #BoehringerIngelheim #CIIE #sanità #ecosistemaCinese

Expertos y autoridades se reunieron en Sevilla para debatir sobre el futuro de la sanidad ante los retos de la longevidad y la cronicidad. 🌱💉

Evento de Boehringer Ingelheim.

Lee más: miniurl.cl/cx1iem

#Sanidad #Longevidad #Cronicidad #Salud #BoehringerIngelheim

Boehringer, Click DTx for schizophrenia clears pivotal trial Boehringer Ingelheim and Click Therapeutics have revealed the data behind their pivotal trial of a digital therapeutic for schizophrenia.

#Boehringer #ClickDTx #schizophrenia #mentalhealth #psychiatry #BoehringerIngelheim #ECNP #phase3 #CONVOKEtrial #CT155 #CAINSMAP #interactivepsychosocialintervention #antipsychoticdrugtreatment #prescriptiondigitaltherapeutics #breakthroughdevicestatus #FDA
zurl.co/OXeAl

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role New trial data backs the use of Boehringer Ingelheim's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

Fresh from a return to #oncology with the FDA approval of #Hernexeos as a treatment for HER2-positive non-small cell #lungcancer (NSCLC), #BoehringerIngelheim is racing to expand its label, with #Bayer in hot pursuit.

pharmaphorum.com/news/esmo-bo...

#BoehringerIngelheim and #ClickTherapeutics have revealed the data from their pivotal trial of #digitaltherapeutic (DTx) CT-155 for #schizophrenia, which has shown efficacy against some of the symptoms that are hardest to address with drug therapies.

pharmaphorum.com/news/boehrin...

🩺 Boehringer Ingelheim reunió a más de 20 asociaciones en su ‘Patient Day’ para poner la voz del paciente como motor de innovación sanitaria.

Lee más 👉https://miniurl.cl/kqfxlv

#VozDelPaciente #InnovaciónEnSalud #BoehringerIngelheim

Expertos abogan por integrar la salud en todas las políticas públicas para abordar los retos sanitarios del futuro - Corresponsables Boehringer Ingelheim ha reafirmado su compromiso con un enfoque integral de la salud a través de la celebración de su encuentro “Horizonte Salud en todas las políticas”. El evento ha […]

🏆 Boehringer Ingelheim ha celebrado la 38ª edición del Premio Boehringer Ingelheim al Periodismo y la Divulgación en Salud.

🔗 www.corresponsables.com/actualidad/e...

#PremiosBoehringer #Salud #BoehringerIngelheim

Bovela® cumple diez años al servicio de la protección inteligente frente a la BVD En 2015, Boehringer Ingelheim lanzó al mercado la primera vacuna viva modificada (MLV) frente a la BVD que garantizaba al 100 % la protección fetal, incluyendo cepas no citopáticas de los ge ...

En 2015, #BoehringerIngelheim lanzó al mercado la primera #vacuna viva modificada (MLV) frente a la BVD que garantizaba al 100 % la protección fetal, incluyendo cepas no citopáticas de los genotipos BVDV-1 y BVDV-2

🎬 New short video guide: Learn how the #PatientPathwayToolkit helps map care & identify barriers.
✔ What’s inside
✔ How to use it
✔ Where to access it
📽️ Watch now at the Toolkit resource page: bit.ly/48bilnr
#AdvocacyTools #PatientLedChange #EPAI #Patvocates #BoehringerIngelheim

Face à la menace des #droitsdedouane américains, les laboratoires misent sur le Mexique ( #Bayer, #BoehringerIngelheim, #AstraZeneca et #Carnot ont annoncé cette semaine 600 millions de dollars d'investissements au #Mexique.

Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app

#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD

#ClickTherapeutics and #BoehringerIngelheim make progress in software-enhanced drug treatment for #schizophrenia with a positive phase 3 trial of their CT-155 app.

pharmaphorum.com/news/click-b...

Bayer files HER2+ lung cancer drug in China Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.

#Bayer's rivalry with #BoehringerIngelheim in the development of medicines for HER2-mutated non-small cell lung cancer (#NSCLC) has been elevated by a filing for its drug in #China.